Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.63 |
| ▸ | MAP3K8 | P41279 | 6/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 2/20 | 0.47 |
| ▸ | GAK | O14976 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769778 | 0.88 | EGFR (0.68) | EGFRERBB2MAP3K8MAPK13EIF2AK2 | |
| SCHEMBL5111293 | 0.83 | MAP3K8 (0.79) | EGFRERBB2MAP3K8MAPK13EIF2AK2 | |
| SCHEMBL4766981 | 0.77 | EGFR (0.69) | EGFRERBB2MAP3K8PDE4BGAK | |
| SCHEMBL5119154 | 0.77 | MAP3K8 (0.73) | EGFRERBB2MAP3K8MAPK13MAPK12 | |
| SCHEMBL5124937 | 0.74 | MAP3K8 (0.71) | EGFRERBB2MAP3K8MAPK13EIF2AK2 | |
| SCHEMBL6382015 | 0.73 | EGFR (0.69) | EGFRERBB2MAP3K8PDE4BGAK | |
| SCHEMBL6642821 | 0.73 | MAP2K1 (0.50) | EGFRERBB2MAP2K1RAF1 | |
| SCHEMBL5111372 | 0.73 | MAP3K8 (0.67) | EGFRMAP3K8MAPK13EIF2AK2MAPK12 | |
| SCHEMBL4776035 | 0.73 | MAP3K8 (1.00) | MAP3K8MAPK13EIF2AK2MAPK12MAPK11 | |
| SCHEMBL4766912 | 0.72 | MAP3K8 (0.79) | EGFRERBB2MAP3K8MAPK13EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CNKSR1, DTYMK | EGFR 2871/4885ERBB2 1101/4885MAP3K8 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.